Erratum: Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (British Journal of Cancer (2015) 112, (1626-1635)) doi: 10.1038/bjc.2015.109;Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

British Journal of Cancer

Volumn 112, Issue 10, 2015, Pages 1626-1635

  Hafeez, S ^a,b   Horwich, A ^a,b   Omar, O ^a   Mohammed, K ^a   Thompson, A ^a   Kumar, P ^a   Khoo, V ^a   Van As, N ^a   Eeles, R ^a,b   Dearnaley, D ^a,b   Huddart, R ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

bladder cancer; chemotherapy; cystectomy; organ preservation; radiotherapy; transitional cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PRESERVATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURGICAL PATIENT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BLADDER; CARCINOMA, TRANSITIONAL CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; ORGAN PRESERVATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; URINARY BLADDER;

EID: 84929275018     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.132     Document Type: Erratum

References (31)

1. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. (2005). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-Analysis of individual patient data advanced bladder cancer (ABC) meta-Analysis collaboration. Eur Urol 48: 202-205discussion 205-6
2. Advanced Bladder Cancer Meta-Analysis Collaboration. (2003). Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet 361: 1927-1934
3. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315-322
4. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. (2014). Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25: 152-165
5. Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, Kiltie AE. (2010). MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 70: 7017-7026
6. Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA. (2011). Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 29: 733-738
7. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. (1996). Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2901-2907
8. deVere White RW, Lara Jr. PN, Goldman B, Tangen CM, Smith DC, Wood Jr. DP, Hussain MH, Crawford ED. (2009). A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 181: 2476-2480discussion 2480-2481
9. Deyo RA, Cherkin DC, Ciol MA. (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619
10. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. (2009). Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27: 4055-4061
11. Efstathiou JA, Spiegel DY, ShipleyWU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL. (2012). Long-Term outcomes of selective bladder preservation by combinedmodality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61: 705-711
12. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, ShipleyWU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012 (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63: 45-57
13. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-Term results of the BA06 30894 trial. J Clin Oncol 29: 2171-2177
14. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood Jr. DP, Raghavan D, Crawford ED. (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866
15. Hautmann RE, de Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T. (1999). The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 161: 422-427discussion 427-428
16. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. (2010). Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28: 4912-4918
17. Huddart R, Birtle A, Lewis R, Bahl A, Falconer A, Maynard L, Hall E. (2012). Results of the SPARE feasibility study-selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder (CRUK/07/011). Int J Radiat Oncol Biol Phys 84: S119-S120
18. Huddart R, McDonald F, Hafeez S, Warren-Oseni K, Taylor H, Thompson A, Khoo V, Harris V, McNair H, Mohammed K, Thomas K, Jones K, Dearnaley D, Horwich A. (2014). Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy). J Clin Oncol 32(4-suppl): Abstract 291
19. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA. BC2001 Investigators. (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366: 1477-1488
20. Kessler TM, Burkhard FC, Studer UE. (2005). Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am 32: 165-175
21. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. (2014). Long-Term outcomes in patients with muscle-invasive bladder cancer after selective bladderpreserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32: 3801-3809
22. Mitin T, Hunt D, ShipleyWU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. (2013). Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 14: 863-872
23. Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan JL. (2011). Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials 12: 78
24. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. (2014). Critical analysis of bladder sparing with trimodal therapy in muscleinvasive bladder cancer: a systematic review. Eur Urol 66: 120-137
25. Pruthi RS, Nix J, McRackan D, Hickerson A, NielsenME, RaynorM, Wallen EM. (2010). Robotic-Assisted laparoscopic intracorporeal urinary diversion. Eur Urol 57: 1013-1021
26. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. (2002). Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-Term results. J Clin Oncol 20: 3061-3071
27. Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, van Tinteren H, Herr H. (1992). The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 147: 606-608
28. Steel G. (2002). Basic Clinical Radiobiology. III edn (Oxford University Press
29. Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M. (2003). Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97: 1644-1652
30. Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, Heney NM, Shipley WU. (2001) Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58: 380-385
31. Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU. (2003). Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-Term survivors. J Urol 170: 1772-1776